Literature DB >> 11859199

Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases.

Mahul B Amin1, Mitual B Amin, Pheroze Tamboli, Javid Javidan, Hans Stricker, Mariza de-Peralta Venturina, Anita Deshpande, Mani Menon.   

Abstract

Just two and a half decades ago adult renal cell neoplasms, i.e., those arising from the renal tubules or collecting duct epithelium, were subdivided into two major subtypes: "clear cell carcinoma" and "granular cell carcinoma." Subsequent detailed morphologic and/or cytogenetic studies have resulted in the recognition of several distinctive subtypes of adult renal epithelial neoplasms, which has led to the promulgation of a refined contemporary histologic classification of these tumors. This study examines the prognostic significance of histologic subtyping in accordance with the new classification in a consecutive series of 405 cases treated at a single institution. Cases were histologically classified into 28 (7%) benign tumors [27 (6.7%) renal oncocytomas, 1 (0.2%) metanephric adenoma] and 377 (93%) malignant tumors [255 (63%) conventional (clear cell) renal cell carcinoma, 75 (18.5%) papillary renal cell carcinoma, 24 (5.9%) chromophobe renal cell carcinoma, and 23 (5.7%) renal cell carcinoma, unclassified]. A total of 25 (6.6%) malignant tumors showed evidence of sarcomatoid change. Kaplan-Meier survival analysis with log-rank test showed histologic type (p = 0.002), Fuhrman's nuclear grade (p = 0.001), TNM stage (p = 0.001), vascular invasion (p = 0.001), and necrosis (p = 0.001) to be significantly associated with disease-specific survival and progression-free survival, based on follow-up of 368 patients (mean 64.5 months, median 56 months). The 5-year disease-specific survival for chromophobe renal cell carcinoma, papillary renal cell carcinoma, conventional (clear cell) renal cell carcinoma, and renal cell carcinoma, unclassified was 100%, 86%, 76%, and 24%, respectively; no patient with a benign tumor diagnosis progressed or died of disease. The 5-year progression-free survival for chromophobe renal cell carcinoma, papillary renal cell carcinoma, conventional (clear cell) renal cell carcinoma, and renal cell carcinoma, unclassified was 94%, 88%, 70%, and 18%, respectively. Malignant tumors with sarcomatoid change had a 35% and 27%, 5-year disease-specific and progression-free survival, respectively. Cox proportional hazards regression analysis showed TNM stage (p = 0.001), nuclear grade (p = 0.01), and necrosis (p = 0.05) to be significant predictors of disease-specific survival. In conclusion, our study shows that the histologic categorization of adult renal epithelial neoplasms performed by routine light microscopic hematoxylin and eosin-based examination in accordance with the contemporary classification scheme has prognostic utility.

Entities:  

Mesh:

Year:  2002        PMID: 11859199     DOI: 10.1097/00000478-200203000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  155 in total

1.  Cutaneous metastasis of renal cell carcinoma: a report of two cases.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

Review 2.  Should there be a size limit for elective nephron-sparing surgery?

Authors:  Kent G Krejci; Bradley C Leibovich
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

3.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

4.  Pathological implications of areas of lower enhancement on contrast-enhanced computed tomography in renal-cell carcinoma: additional information for selecting candidates for surveillance protocols.

Authors:  Miguel Villalobos-Gollás; Bernardo Aguilar-Davidov; Carolina Culebro-García; Martha O Gómez-Alvarado; Priscila Rojas-Garcia; Raúl Ibarra-Fombona; Norma Uribe-Uribe; Guillermo Feria-Bernal; Ricardo Castillejos-Molina; Mariano Sotomayor; Fernando Gabilondo; Francisco Rodríguez-Covarrubias
Journal:  Int Urol Nephrol       Date:  2012-05-22       Impact factor: 2.370

Review 5.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

6.  Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.

Authors:  Christian Eichelberg; Sarah Minner; Hendrik Isbarn; Eike Burandt; Luigi Terracciano; Holger Moch; Alexandra Kell; Roman Heuer; Felix K Chun; Guido Sauter; Margit Fisch; Pierre Tennstedt
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

7.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

Review 8.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Urol Clin North Am       Date:  2018-06-15       Impact factor: 2.241

Review 9.  Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Authors:  Shreyas Gandhi; Gaurav Vasisth; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2017-04-11       Impact factor: 1.862

10.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.